BRCA2 and in situ carcinoma: Additionally, both lesions exhibited frequent alterations in DDR genes, with CIS lesions showing a higher mutational rate in homologous recombination (HR)-related genes (BRCA1, BRCA2, ATM), whereas pTa HG/papillary pT1 HG lesions specifically exhibited a high frequency of ERCC2 mutations [11].